This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

Prince Harry embarks on a new courtroom battle against British tabloids in his case against Rupert Murdoch’s News Group ...

Recurrent respiratory papillomatosis (RRP) is a disease of the upper airway presenting with exophytic wart-like lesions. These lesions are considered benign with less than a 1–5% chance of malignant ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

CRISPR Therapeutics is a mid-stage biotech specializing in gene editing. The company has just one product ... granted the Regenerative Medicine Advanced Therapy (RMAT) designation to the company's ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment, which uses ...